Oasmia Pharmaceutical AB | Income Statement
Fiscal year is May-April. All values SEK Thousands.
2014
2015
2016
2017
2018
2019
Sales/Revenue
60.00
2,070.00
6,373.00
172.00
3,169.00
1,980
Cost of Goods Sold (COGS) incl. D&A
102,602.00
48,985.00
42,660.00
49,518.00
108,006.00
122,867
Gross Income
102,542.00
46,915.00
36,287.00
49,346.00
104,837.00
120,887
SG&A Expense
-
60,739.00
-
-
-
-
EBIT
102,542.00
107,654.00
133,171.00
139,310.00
104,837.00
120,887
Unusual Expense
4,250.00
26.00
-
-
1,300.00
-
Non Operating Income/Expense
216.00
608.00
-
1,164.00
139.00
755
Interest Expense
7,212.00
9,431.00
8,369.00
19,803.00
14,390.00
18,079
Pretax Income
105,112.00
117,497.00
141,539.00
160,243.00
118,013.00
138,192
Consolidated Net Income
105,112.00
117,497.00
141,539.00
160,243.00
118,013.00
171,014
Net Income
105,112.00
117,497.00
141,539.00
160,243.00
118,007.00
171,020
Net Income After Extraordinaries
105,112.00
117,497.00
141,539.00
160,243.00
118,007.00
171,020
Net Income Available to Common
105,112.00
117,497.00
141,539.00
160,243.00
118,007.00
171,020
EPS (Basic)
1.24
1.25
1.36
1.39
0.71
0.88
Basic Shares Outstanding
84,926.30
93,708.70
104,032.90
115,525.80
166,196.00
193,368
EPS (Diluted)
1.24
1.25
1.36
1.39
0.71
0.88
Diluted Shares Outstanding
84,926.30
93,708.70
104,032.90
115,525.80
166,196.00
193,368
EBITDA
97,601.00
102,464.00
128,367.00
134,802.00
100,043.00
114,300
Other Operating Expense
-
-
96,884.00
89,964.00
-
-
Non-Operating Interest Income
176.00
170.00
1.00
34.00
53.00
19
Minority Interest Expense
-
-
-
-
6.00
6
About Oasmia Pharmaceutical AB
View Profile
